Government-Owned Inventions; Availability for Licensing, 74549-74551 [E6-21029]
Download as PDF
<![CDATA[
Federal Register / Vol. 71, No. 238 / Tuesday, December 12, 2006 / Notices
Vaccine for Dengue Virus
Description of Technology: The
claimed invention relates to viable
chimeric dengue viruses or their derived
recombinant mutants for use as vaccines
against dengue and other flavivirus
diseases, including tick-borne
encephalitis and West Nile encephalitis.
Dengue is a mosquito-transmitted viral
disease which occurs in tropical and
subtropical regions throughout the
world. Inactivated whole dengue virus
vaccines have been shown to be
insufficiently immunogenic and live
dengue virus vaccines prepared by
serial passage in cell culture have not
been shown to be consistently
attenuated. A dengue vaccine is still not
available. The present invention
represents a technical breakthrough,
which provides new approaches to
dengue vaccines by construction of
chimeric dengue viruses of all four
serotypes and strategic modification to
produce attenuated virus strains.
Several fields of use remain available for
licensing.
Applications: Prevention of dengue
outbreaks, severe and fatal dengue
caused by dengue viruses, a major
public health problem in tropical and
subtropical regions.
Inventors: Ching-juh Lai, et al.
(NIAID).
Patent Status: U.S. Patent 6,184,024
issued 06 Feb 2001 (HHS Reference No.
E–171–1988/1–US–02); U.S. Patent
6,676,926 issued 13 Jan 2004 (HHS
Reference No. E–171–1988/1–US–03).
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301–435–4646;
soukasp@mail.nih.gov.
jlentini on PROD1PC65 with NOTICES
Murine Monoclonal Antibodies
Effective To Treat Respiratory
Syncytial Virus
Description of Technology: Available
for licensing through a Biological
Materials License Agreement are the
murine MAbs described in Beeler et al,
‘‘Neutralization epitopes of the F
glycoprotein of respiratory syncytial
virus: effect of mutation upon fusion
function,’’ J Virol. 1989 Jul;63(7):2941–
2950. The MAbs that are available for
licensing are the following: 1129, 1153,
1142, 1200, 1214, 1237, 1112, 1269, and
1243. One of these MAbs, 1129, is the
basis for a humanized murine MAb (see
U.S. Patent 5,824,307 to humanized
1129 owned by MedImmune, Inc.),
recently approved for marketing in the
United States. MAbs in the panel
reported by Beeler et al. have been
shown to be effective therapeutically
when administered into the lungs of
VerDate Aug<31>2005
18:00 Dec 11, 2006
Jkt 211001
cotton rats by small-particle aerosol.
Among these MAbs several exhibited a
high affinity (approximately 109M–1)
for the RSV F glycoprotein and are
directed at epitopes encompassing
amino acid 262, 272, 275, 276 or 389.
These epitopes are separate,
nonoverlapping and distinct from the
epitope recognized by the human Fab of
U.S. Patent 5,762,905 owned by The
Scripps Research Institute.
Applications: Research and drug
development for treatment of respiratory
syncytial virus.
Inventors: Robert M. Chanock, Brian
R. Murphy, Judith A. Beeler, and
Kathleen L. van Wyke Coelingh (NIAID).
Patent Status: HHS Reference No. B–
056–1994/1—Research Tool.
Licensing Status: Available for nonexclusive licensing under a Biological
Materials License Agreement.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov.
Dated: December 1, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–21028 Filed 12–11–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301–
496–7057; fax: 301–402–0220. A signed
Confidential Disclosure Agreement will
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
74549
be required to receive copies of the
patent applications.
Noncovalent HIV Env-CD4 Complexes
as HIV Vaccines
Description of Technology: HIV
vaccine technology based on HIV
envelope protein (Env) have been less
successful than anticipated to date. One
possible reason for this is the potential
conformational masking of neutralizing
epitopes. The current technology
combines HIV Env and cell surface
polypeptides CD4 in non-covalent
complexes to expose epitopes not
present on the uncomplexed Env
molecules. These complexes can thus be
used to elicit neutralizing antibodies
when used as vaccines, immunogenic
compositions or immunotherapies. The
CD4 inducing epitopes found in regions
of the virus that are most conserved
across clades are unmasked and
immune sera generated with this
technology neutralized primary HIV–1
viruses from several clades.
Additionally, cell surface polypeptide
CD4 is in its native conformation and
masked by Env, therefore it is unlikely
to induce autoantibodies.
Applications and Advantages: (1) HIV
vaccine based on conformationally
masked epitopes; (2) Presents epitopes
to immune system that are the same or
similar as with actual HIV infection; (3)
Multiple copies of Env may enhance
immune response and limit dosage.
Inventors: Jinhai Wang and Michael
Norcross (CDER/FDA).
Patent Status: U.S. Provisional
Application No. 60/711,985 filed 25
Aug 2005 (HHS Reference No. E–173–
2005/0–US–01); PCT Application filed
25 Aug 2006 (HHS Reference No. E–
173–2005/1–PCT–01).
Licensing Contact: Susan Ano, PhD;
301–435–5515; anos@mail.nih.gov.
Collaborative Research Opportunity:
The FDA Center for Drug Evaluation
and Research is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this HIV Env-CD4
technology. Please contact Beatrice A.
Droke at 301/827–7008 or
bea.droke@fda.hhs.gov for more
information.
Modified Bacterial Strain for Otitis
Media Vaccine
Description of the Technology: This
invention relates to a strain of Moraxella
catarrhalis containing a gene mutation
that prevents endotoxic
lipooligosaccharide (LOS) synthesis and
potential use of the mutant for
developing novel vaccines against the
pathogen, for which there is currently
E:\FR\FM\12DEN1.SGM
12DEN1
74550
Federal Register / Vol. 71, No. 238 / Tuesday, December 12, 2006 / Notices
no licensed vaccine. M. catarrhalis is
one of the causative agents of otitis
media (middle ear infection), sinusitis,
and lung infections. The mutant is
defective in the lpxA gene, whose
enzyme product is relevant in lipid A
biosynthesis (lipid A is part of the LOS).
The nontoxic mutant was found to elicit
high levels of antibodies with
bactericidal activity and provided
protection against wild type bacterial
challenge. Use of this mutant bacterium
is envisioned as a new approach for
vaccines against M. catarrhalis.
Applications: Otitis media vaccine,
sinusitis, and lung infections.
Inventors: Xin-Xing Gu and Daxin
Peng (NIDCD).
Patent Status: U.S. Provisional
Application No. 60/577,244 filed 04 Jun
2004 (HHS Reference No. E–174–2004/
0–US–01); U.S. Provisional Application
No. 60/613,139 filed 23 Sep 23 (HHS
Reference No. E–174–2004/1–US–01);
PCT Application No. PCT/US2005/
019479 filed 03 Jun 2005 (HHS
Reference No. E–174–2004/2–PCT–01).
Licensing Status: Available for nonexclusive licensing—biological
materials.
Licensing Contact: Susan Ano, PhD;
301/435–5515; anos@mail.nih.gov.
Collaborative Research Opportunity:
The Vaccine Research Section in the
National Institute on Deafness and
Other Communication Disorders
(NIDCD) is seeking statements of
capability or interest from parties
interested in collaborative research.
NIDCD is interested in developing outer
membrane proteins (OMP), outer
membrane vesicle (OMV), and whole
cell vaccines generated from the mutant.
The mutant strain can also be used as
an effective vehicle to express and
deliver protective antigens from other
important human pathogens. Please
contact Dr. Xin-Xing Gu by phone (301–
402–2456) or e-mail
(guxx@nidcd.nih.gov) for more
information.
jlentini on PROD1PC65 with NOTICES
A Method With Increased Yield for
Production of Polysaccharide-Protein
Conjugate Vaccines Using Hydrazide
Chemistry
Description of Technology: Current
methods for synthesis and
manufacturing of polysaccharideprotein conjugate vaccines employ
conjugation reactions with low
efficiency (about twenty percent). This
means that up to eighty percent of the
added activated polysaccharide (PS) is
lost. In addition, inclusion of a
chromatographic process for
purification of the conjugates from
unconjugated PS is required.
VerDate Aug<31>2005
18:00 Dec 11, 2006
Jkt 211001
The present invention utilizes the
characteristic chemical property of
hydrazide groups on one reactant to
react with aldehyde groups or cyanate
esters on the other reactant with an
improved conjugate yield of at least
sixty percent. With this conjugation
efficiency the leftover unconjugated
protein and polysaccharide would not
need to be removed and thus the
purification process of the conjugate
product can be limited to diafiltration to
remove the by-products of small
molecules. The new conjugation
reaction can be carried out within one
or two days with reactant
concentrations between 1 and 25 mg/mL
at PS/protein ratios from 1:2 to 3:1, at
temperatures between 4 and 40 degrees
Centigrade, and in a pH range of 5.5 to
7.4, optimal conditions varying from PS
to PS.
Application: Cost effective and
efficient manufacturing of conjugate
vaccines.
Inventors: Che-Hung Robert Lee and
Carl E. Frasch (CBER/FDA).
Patent Status: U.S. Patent Application
No. 10/566,899 filed 01 Feb 2006,
claiming priority to 06 Aug 2003 (HHS
Reference No. E–301–2003/0–US–10);
U.S. Patent Application No. 10/566,898
filed 01 Feb 2006, claiming priority to
06 Aug 2003 (HHS Reference No. E–
301–2003/1–US–02); International
rights available.
Licensing Status: Available for nonexclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov.
inhibitors of HIV envelope mediated
cell fusion.
Development Status: The technology
is currently in pre-clinical stage of
development.
Inventors: G. Marius Clore et al.
(NIDDK).
Publications:
1. JM Louis et al. Design and
properties of NCCG-gp41, a chimeric
gp41 molecule with nanomolar HIV
fusion inhibitory activity. J Biol Chem.
2001 Aug 3;276(31):29485–29489.
2. CA Bewley et al. Design of a novel
peptide inhibitor of HIV fusion that
disrupts the internal trimeric coiled-coil
of gp41. J Biol Chem. 2002 Apr
19;277(16):14238–14245.
3. JM Louis et al. Covalent trimers of
the internal N-terminal trimeric coiledcoil of gp41 and antibodies directed
against them are potent inhibitors of
HIV envelope-mediated cell fusion. J
Biol Chem. 2003 May 30;278(22):20278–
20285.
4. JM Louis et al. Characterization and
HIV–1 fusion inhibitory properties of
monoclonal Fabs obtained from a
human non-immune phage library
selected against diverse epitopes of the
ectodomain of HIV–1 gp41. J Mol Biol.
2005 Nov 11;353(5):945–951.
Patent Status: U.S. Patent Application
No. 10/499,094 filed 14 Jun 2004 (HHS
Reference No. E–252–2001/0–US–03);
EP application 02795951.9 and IN
application 1535/CHENP/2004.
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Susan Ano, Ph.D.;
301/435–5515; anos@mail.nih.gov.
HIV Entry Inhibitor
Description of Technology: The
technology relates to a chimeric
molecule, NCCG-gp41, in which the
internal trimeric helical coiled-coil of
the ectodomain of gp41 is fully exposed
and stabilized by both fusion to a
minimal ectodomain core of gp41 and
by engineered intersubunit disulfide
bonds. NCCG-gp41 inhibits HIV envelope
mediated cell fusion at nanomolar
concentrations with an IC50 of 16 nM. It
is proposed that NCCG-gp41 targets the
exposed C-terminal region of the gp41
ectodomain in its pre-hairpin
intermediate state, thereby preventing
the formation of the fusogenic form of
the gp41 ectodomain that comprises a
highly stable trimer of hairpins arranged
in a six-helix bundle. Antibodies have
been raised against NCCG-gp41 that
inhibit HIV envelope mediated cell
fusion.
Applications: (1) Entry inhibitor HIV
therapeutic; (2) HIV/AIDS vaccine; (3)
As a component of a high throughput
screening assay for small molecule
Subgenomic Replicons of the Flavivirus
Dengue
Description of Technology: Dengue
virus, with its four serotypes Den-1 to
Den-4, is the most important member of
the Flavivirus genus with respect to
infection of human producing diseases
that range from flu-like symptoms of
dengue fever (DF) to severe or fatal
illness of dengue hemorrhagic fever
(DHF) and dengue shock syndrome
(DSS). Dengue outbreaks continue to be
a major public health problem in
densely populated areas of the tropical
and subtropical regions, where
mosquito vectors are abundant. This
invention relates to the construction of
all four types of dengue subgenomic
replicons (chromosome and plasmid
which contain genetic information
necessary for their own replication)
containing large deletions in the
structural region (C-preM–E) of the
genome. Immunization using these
replicons should be effective in eliciting
not only a humoral-mediated immune
response but also a cell-mediated
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
E:\FR\FM\12DEN1.SGM
12DEN1
Federal Register / Vol. 71, No. 238 / Tuesday, December 12, 2006 / Notices
immune response. These replicons
should be safer than a live attenuated
vaccine because they cannot cause
disease in the host and they should be
better than subunit vaccines because
they can replicate in the host.
Applications: Prevention of severe
and/or fatal human disease caused by
dengue virus, a major health concern in
tropical and subtropical regions.
Inventor: Xiaowu Pang (CBER/FDA).
Patent Status: U.S. Patent Application
10/656,721 filed 05 Sep 2003, claiming
priority to 09 Mar 2001 (HHS Reference
No. E–228–2000/0–US–03).
Licensing Status: Available for nonexclusive or exclusive licensing.
Licensing Contact: Peter A. Soukas,
J.D.; 301/435–4646;
soukasp@mail.nih.gov.
Dated: December 1, 2006.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E6–21029 Filed 12–11–06; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
jlentini on PROD1PC65 with NOTICES
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
ARH3, a Therapeutic Target for Cancer,
Ischemia, and Inflammation
Description of Technology: ADPribosylation is important in many
VerDate Aug<31>2005
18:00 Dec 11, 2006
Jkt 211001
cellular processes, including DNA
replication and repair, maintenance of
genomic stability, telomere dynamics,
cell differentiation and proliferation,
and necrosis and apoptosis. Poly-ADPribose is important in a number of
critical physiological processes such as
DNA repair, cellular differentiation, and
carcinogenesis. Until recently, only one
human enzyme, PARG, had been
identified that degrades the ADP-ribose
polymer. Another ADP-ribose, O-acetylADP ribose, is formed via the
deacetylation of proteins, such as acetylhistone, by proteins in the Sir2 family.
Sir2 proteins have been implicated in
regulation of chromatin structure and
longevity.
The NIH announces the discovery of
a novel PARG-like enzyme, ARH3.
ARH3 possesses PARG activity, yet is
structurally distinct from PARG. ARH3
also hydrolyzes O-acetyl-ADP-ribose,
and is the only protein recognized to
date with such activity. ARH3 thus
appears to function in two important
signaling pathways, serving to regulate
both poly-ADP-ribose and O-acetylADP-ribose levels. It may affect
chromatin structure through effects on
both pathways. Since ARH3 structures
differs from PARG or other enzymes that
participate in these pathways, it may be
possible to design specific inhibitors to
target both the poly-ADP-ribose and Sir2
pathways. These drugs may be used as
anticancer agents, radiosensitizers or
antiviral agents, or for treating disorders
involving oxidative damage, such as
acute tissue injury, ischemia, and
inflammation.
Applications: (1) Development of
therapeutics for cancer or disorders
associated with excessive DNA damage;
(2) Development of therapeutics for
diseases involving oxidative damage,
such as acute tissue injury, ischemia
and inflammation.
Market: (1) Patients with
chemotherapy-resistant tumors, or with
cancers that are genetically deficient in
DNA repair; (2) Patients with
inflammatory or ischemia/reperfusion
diseases, particularly those associated
with acute cardiovascular disease.
Development Status: Early stage.
Inventors: Joel Moss et al. (NHLBI).
Related Publications:
1. S Oka, J Kato, J Moss. Identification
and characterization of a mammalian
39-kDa poly(ADP-ribose)
glycohydrolase. J Biol Chem. 2006 Jan
13;281(2):705–713.
2. T Ono, A Kasamatsu, S Oka, J Moss.
The 39-kDa poly(ADP-ribose)
glycohydrolase ARH3 hydrolyzes Oacetyl-ADP-ribose, a product of the Sir2
family of acetyl-histone deacetylases.
Proc Natl Acad Sci USA 2006 Nov
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
74551
7;103(45):16687–16691. Epub 2006 Oct
30, doi 10.1073/pnas.0607911103.
Patent Status: U.S. Provisional
Application No. 60/716,807 filed 12 Sep
2005 (HHS Reference No. E–347–2004/
0-US–01); PCT Application No. PCT/
US2006/035771 filed 12 Sep 2006 (HHS
Reference No. E–347–2004/0–PCT–02).
Licensing Status: Available for
exclusive or non-exclusive licensing.
Licensing Contact: Tara L. Kirby, PhD;
301/435–4426; tarak@mail.nih.gov.
Collaborative Research Opportunity:
The Pulmonary Critical Care Medicine
Branch in the National Heart, Lung, and
Blood Institute is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the invention. Please
contact Marianne Lynch in the NHLBI
Office of Technology Transfer and
Development by phone (301–594–4094)
or e-mail (lynchm@nhlbi.nih.gov) for
more information.
Antisera To Detect Phosphorylated
Phosphoinositide-Dependent Kinase 1
(PDK–1)
Description of Technology: PDK–1
phosphorylates and activates a number
of cellular kinases, and plays a major
role in insulin and growth factor
signaling. PDK–1 also represents a
promising drug target for a number of
cancers. Autophosphorylation at Ser244
(mouse) or Ser241 (human) is critical for
PDK–1 activity.
Available for licensing are polyclonal
rabbit antisera that specifically detect
mouse PDK–1 protein phosphorylated at
Ser244. These antisera are also expected
to be specific for the human PDK–1
protein phosphorylated at Ser241.
Applications: (1) Tool for screening
PDK–1 autophosphorylation inhibitors
for cancer and other indications; (2)
Tool for studying insulin and growth
factor signaling.
Inventor: Michael J. Quon (NCCAM).
Publication: MJ Wick, FJ Ramos, H
Chen, MJ Quon, LQ Dong, F Liu. Mouse
3-phosphoinositide-dependent protein
kinase-1 undergoes dimerization and
trans-phosphorylation in the activation
loop. J Biol Chem. 2003 Oct
31;278(44):42913–42919.
Patent Status: HHS Reference No. E–
330–2003/0—Research Tool.
Licensing Status: This technology is
available as a research tool under a
Biological Materials License.
Licensing Contact: Tara Kirby, PhD;
301/435–4426; tarak@mail.nih.gov
Collaborative Research Opportunity:
The NIH, NCCAM, Diabetes Unit is
seeking statements of capability or
interest from parties interested in
collaborative research to further
E:\FR\FM\12DEN1.SGM
12DEN1
]]>Agencies
[Federal Register Volume 71, Number 238 (Tuesday, December 12, 2006)]
[Notices]
[Pages 74549-74551]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-21029]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301-496-7057; fax: 301-402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Noncovalent HIV Env-CD4 Complexes as HIV Vaccines
Description of Technology: HIV vaccine technology based on HIV
envelope protein (Env) have been less successful than anticipated to
date. One possible reason for this is the potential conformational
masking of neutralizing epitopes. The current technology combines HIV
Env and cell surface polypeptides CD4 in non-covalent complexes to
expose epitopes not present on the uncomplexed Env molecules. These
complexes can thus be used to elicit neutralizing antibodies when used
as vaccines, immunogenic compositions or immunotherapies. The CD4
inducing epitopes found in regions of the virus that are most conserved
across clades are unmasked and immune sera generated with this
technology neutralized primary HIV-1 viruses from several clades.
Additionally, cell surface polypeptide CD4 is in its native
conformation and masked by Env, therefore it is unlikely to induce
autoantibodies.
Applications and Advantages: (1) HIV vaccine based on
conformationally masked epitopes; (2) Presents epitopes to immune
system that are the same or similar as with actual HIV infection; (3)
Multiple copies of Env may enhance immune response and limit dosage.
Inventors: Jinhai Wang and Michael Norcross (CDER/FDA).
Patent Status: U.S. Provisional Application No. 60/711,985 filed 25
Aug 2005 (HHS Reference No. E-173-2005/0-US-01); PCT Application filed
25 Aug 2006 (HHS Reference No. E-173-2005/1-PCT-01).
Licensing Contact: Susan Ano, PhD; 301-435-5515; anos@mail.nih.gov.
Collaborative Research Opportunity: The FDA Center for Drug
Evaluation and Research is seeking statements of capability or interest
from parties interested in collaborative research to further develop,
evaluate, or commercialize this HIV Env-CD4 technology. Please contact
Beatrice A. Droke at 301/827-7008 or bea.droke@fda.hhs.gov for more
information.
Modified Bacterial Strain for Otitis Media Vaccine
Description of the Technology: This invention relates to a strain
of Moraxella catarrhalis containing a gene mutation that prevents
endotoxic lipooligosaccharide (LOS) synthesis and potential use of the
mutant for developing novel vaccines against the pathogen, for which
there is currently
[[Page 74550]]
no licensed vaccine. M. catarrhalis is one of the causative agents of
otitis media (middle ear infection), sinusitis, and lung infections.
The mutant is defective in the lpxA gene, whose enzyme product is
relevant in lipid A biosynthesis (lipid A is part of the LOS). The
nontoxic mutant was found to elicit high levels of antibodies with
bactericidal activity and provided protection against wild type
bacterial challenge. Use of this mutant bacterium is envisioned as a
new approach for vaccines against M. catarrhalis.
Applications: Otitis media vaccine, sinusitis, and lung infections.
Inventors: Xin-Xing Gu and Daxin Peng (NIDCD).
Patent Status: U.S. Provisional Application No. 60/577,244 filed 04
Jun 2004 (HHS Reference No. E-174-2004/0-US-01); U.S. Provisional
Application No. 60/613,139 filed 23 Sep 23 (HHS Reference No. E-174-
2004/1-US-01); PCT Application No. PCT/US2005/019479 filed 03 Jun 2005
(HHS Reference No. E-174-2004/2-PCT-01).
Licensing Status: Available for non-exclusive licensing--biological
materials.
Licensing Contact: Susan Ano, PhD; 301/435-5515; anos@mail.nih.gov.
Collaborative Research Opportunity: The Vaccine Research Section in
the National Institute on Deafness and Other Communication Disorders
(NIDCD) is seeking statements of capability or interest from parties
interested in collaborative research. NIDCD is interested in developing
outer membrane proteins (OMP), outer membrane vesicle (OMV), and whole
cell vaccines generated from the mutant. The mutant strain can also be
used as an effective vehicle to express and deliver protective antigens
from other important human pathogens. Please contact Dr. Xin-Xing Gu by
phone (301-402-2456) or e-mail (guxx@nidcd.nih.gov) for more
information.
A Method With Increased Yield for Production of Polysaccharide-Protein
Conjugate Vaccines Using Hydrazide Chemistry
Description of Technology: Current methods for synthesis and
manufacturing of polysaccharide-protein conjugate vaccines employ
conjugation reactions with low efficiency (about twenty percent). This
means that up to eighty percent of the added activated polysaccharide
(PS) is lost. In addition, inclusion of a chromatographic process for
purification of the conjugates from unconjugated PS is required.
The present invention utilizes the characteristic chemical property
of hydrazide groups on one reactant to react with aldehyde groups or
cyanate esters on the other reactant with an improved conjugate yield
of at least sixty percent. With this conjugation efficiency the
leftover unconjugated protein and polysaccharide would not need to be
removed and thus the purification process of the conjugate product can
be limited to diafiltration to remove the by-products of small
molecules. The new conjugation reaction can be carried out within one
or two days with reactant concentrations between 1 and 25 mg/mL at PS/
protein ratios from 1:2 to 3:1, at temperatures between 4 and 40
degrees Centigrade, and in a pH range of 5.5 to 7.4, optimal conditions
varying from PS to PS.
Application: Cost effective and efficient manufacturing of
conjugate vaccines.
Inventors: Che-Hung Robert Lee and Carl E. Frasch (CBER/FDA).
Patent Status: U.S. Patent Application No. 10/566,899 filed 01 Feb
2006, claiming priority to 06 Aug 2003 (HHS Reference No. E-301-2003/0-
US-10); U.S. Patent Application No. 10/566,898 filed 01 Feb 2006,
claiming priority to 06 Aug 2003 (HHS Reference No. E-301-2003/1-US-
02); International rights available.
Licensing Status: Available for non-exclusive licensing.
Licensing Contact: Peter A. Soukas, J.D.; 301/435-4646;
soukasp@mail.nih.gov.
HIV Entry Inhibitor
Description of Technology: The technology relates to a chimeric
molecule, NCCG-gp41, in which the internal trimeric helical
coiled-coil of the ectodomain of gp41 is fully exposed and stabilized
by both fusion to a minimal ectodomain core of gp41 and by engineered
intersubunit disulfide bonds. NCCG-gp41 inhibits HIV
envelope mediated cell fusion at nanomolar concentrations with an
IC50 of 16 nM. It is proposed that NCCG-gp41
targets the exposed C-terminal region of the gp41 ectodomain in its
pre-hairpin intermediate state, thereby preventing the formation of the
fusogenic form of the gp41 ectodomain that comprises a highly stable
trimer of hairpins arranged in a six-helix bundle. Antibodies have been
raised against NCCG-gp41 that inhibit HIV envelope mediated
cell fusion.
Applications: (1) Entry inhibitor HIV therapeutic; (2) HIV/AIDS
vaccine; (3) As a component of a high throughput screening assay for
small molecule inhibitors of HIV envelope mediated cell fusion.
Development Status: The technology is currently in pre-clinical
stage of development.
Inventors: G. Marius Clore et al. (NIDDK).
Publications:
1. JM Louis et al. Design and properties of NCCG-gp41, a
chimeric gp41 molecule with nanomolar HIV fusion inhibitory activity. J
Biol Chem. 2001 Aug 3;276(31):29485-29489.
2. CA Bewley et al. Design of a novel peptide inhibitor of HIV
fusion that disrupts the internal trimeric coiled-coil of gp41. J Biol
Chem. 2002 Apr 19;277(16):14238-14245.
3. JM Louis et al. Covalent trimers of the internal N-terminal
trimeric coiled-coil of gp41 and antibodies directed against them are
potent inhibitors of HIV envelope-mediated cell fusion. J Biol Chem.
2003 May 30;278(22):20278-20285.
4. JM Louis et al. Characterization and HIV-1 fusion inhibitory
properties of monoclonal Fabs obtained from a human non-immune phage
library selected against diverse epitopes of the ectodomain of HIV-1
gp41. J Mol Biol. 2005 Nov 11;353(5):945-951.
Patent Status: U.S. Patent Application No. 10/499,094 filed 14 Jun
2004 (HHS Reference No. E-252-2001/0-US-03); EP application 02795951.9
and IN application 1535/CHENP/2004.
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Susan Ano, Ph.D.; 301/435-5515;
anos@mail.nih.gov.
Subgenomic Replicons of the Flavivirus Dengue
Description of Technology: Dengue virus, with its four serotypes
Den-1 to Den-4, is the most important member of the Flavivirus genus
with respect to infection of human producing diseases that range from
flu-like symptoms of dengue fever (DF) to severe or fatal illness of
dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). Dengue
outbreaks continue to be a major public health problem in densely
populated areas of the tropical and subtropical regions, where mosquito
vectors are abundant. This invention relates to the construction of all
four types of dengue subgenomic replicons (chromosome and plasmid which
contain genetic information necessary for their own replication)
containing large deletions in the structural region (C-preM-E) of the
genome. Immunization using these replicons should be effective in
eliciting not only a humoral-mediated immune response but also a cell-
mediated
[[Page 74551]]
immune response. These replicons should be safer than a live attenuated
vaccine because they cannot cause disease in the host and they should
be better than subunit vaccines because they can replicate in the host.
Applications: Prevention of severe and/or fatal human disease
caused by dengue virus, a major health concern in tropical and
subtropical regions.
Inventor: Xiaowu Pang (CBER/FDA).
Patent Status: U.S. Patent Application 10/656,721 filed 05 Sep
2003, claiming priority to 09 Mar 2001 (HHS Reference No. E-228-2000/0-
US-03).
Licensing Status: Available for non-exclusive or exclusive
licensing.
Licensing Contact: Peter A. Soukas, J.D.; 301/435-4646;
soukasp@mail.nih.gov.
Dated: December 1, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E6-21029 Filed 12-11-06; 8:45 am]
BILLING CODE 4140-01-P
